Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewSB 265610
Description: Potent CXCR2 antagonist
Chemical Name: N-(2-Bromophenyl)-N'-(7-cyano-1H-benzotriazol-4-yl)urea
Purity: ≥98% (HPLC)
Biological Activity for SB 265610
SB 265610 is a potent CXCR2 antagonist that inhibits CINC-1-mediated but not C5a-mediated Ca2+ mobilization (IC50 values are 3.4 and 6800 nM respectively). Inhibits CINC-induced chemotaxis and attenuates neutrophil accumulation in inflammatory lung injury in vivo.
Licensing Information
Sold for research purposes under agreement from GlaxoSmithKline
Compound Libraries for SB 265610
SB 265610 is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen Antiviral Library. Find out more about compound libraries available from Tocris.
Technical Data for SB 265610
| M. Wt | 357.16 |
| Formula | C14H9BrN6O |
| Storage | Store at RT |
| Purity | ≥98% (HPLC) |
| CAS Number | 211096-49-0 |
| PubChem ID | 9841667 |
| InChI Key | SEDUMQWZEOMXSO-UHFFFAOYSA-N |
| Smiles | O=C(NC3=C(Br)C=CC=C3)NC1=CC=C(C#N)C2=C1NN=N2 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for SB 265610
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 35.72 | 100 | |
| ethanol | 3.57 | 10 |
Preparing Stock Solutions for SB 265610
The following data is based on the product molecular weight 357.16. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.8 mL | 14 mL | 28 mL |
| 5 mM | 0.56 mL | 2.8 mL | 5.6 mL |
| 10 mM | 0.28 mL | 1.4 mL | 2.8 mL |
| 50 mM | 0.06 mL | 0.28 mL | 0.56 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for SB 265610
References for SB 265610
References are publications that support the biological activity of the product.
Auten et al (2001) Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats. J.Pharmacol.Exp.Ther. 299 90 PMID: 11561067
Milatovic et al (2003) Impaired healing of nitrogen mustard wounds in CXCR2 null mice. Wound Repair Regen. 11 213 PMID: 12753603
If you know of a relevant reference for SB 265610, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: SB 265610, SB 265610 supplier, Potent, CXCR2, antagonists, Chemokine, Receptors, SB265610, GlaxoSmithKline, GSK, CXC, 2724, Tocris Bioscience
8 Citations for SB 265610
Citations are publications that use Tocris products. Selected citations for SB 265610 include:
Ha et al (2014) A novel phenylcyclohex-1-enecarbothioamide derivative inhibits CXCL8-mediated chemotaxis through selective regulation of CXCR2-mediated signalling. Br J Pharmacol 171 1551 PMID: 24354854
Bieren et al (2015) Immune Antibodies and Helminth Products Drive CXCR2-Dependent Macrophage-Myofibroblast Crosstalk to Promote Intestinal Repair. PLoS Pathog 11 e1004778 PMID: 25806513
Toh et al (2011) Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol 9 e1001162 PMID: 21980263
Halpern et al (2011) Mesenchymal stem cells promote mammary cancer cell migration in vitro via the CXCR2 receptor. Cancer Lett 308 91 PMID: 21601983
Burton et al (2011) Bone morphogenetic protein receptor II regulates pulmonary artery endothelial cell barrier function. Blood 117 333 PMID: 20724539
Jung et al (2016) CXCR2 Inhibition in Human Pluripotent Stem Cells Induces Predominant Differentiation to Mesoderm and Endoderm Through Repression of mTOR, β-Catenin, and hTERT Activities. Stem Cells Dev 25 1006 PMID: 27188501
Lavoie-Lamoureux et al (2010) IL-4 activates equine neutrophils and induces a mixed inflammatory cytokine expression profile with enhanced neutrophil chemotactic mediator release ex vivo. Am J Physiol Lung Cell Mol Physiol 299 L472 PMID: 20639353
He et al (2018) Circadian Expression of Migratory Factors Establishes Lineage-Specific Signatures that Guide the Homing of Leukocyte Subsets to Tissues. Immunity 49 1175 PMID: 30527911
Do you know of a great paper that uses SB 265610 from Tocris? Please let us know.
Reviews for SB 265610
There are currently no reviews for this product. Be the first to review SB 265610 and earn rewards!
Have you used SB 265610?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.